Tryfonas G I, Tsikopoulos G, Liasidou E, Gavopoulos S, Georgakis G, Badouraki M, Soultanides C
Pediatric Surgical Clinic, Hippokratio General Hospital, Thessaloniki, Greece.
Pediatr Surg Int. 1998 Oct;13(8):590-3. doi: 10.1007/s003830050411.
Hemangioma is the most common tumor of infancy. Most hemangiomas proliferate for 8 to 18 months and then slowly regress over the next 5 to 8 years. So far, steroids have been the established means of treatment, but there have been some reports of the use of interferon-alpha 2a (IFN-A2a) in such tumors. To evaluate the efficacy of IFN-A2a in treating giant hemangiomas in infancy and childhood, we administered it to ten patients aged 4 h to 6.5 years with life-threatening hemangiomas in various parts of the body. The dose used was 3 MU/m2 body surface area subcutaneously every second day. All children had previously received corticosteroids for 2 to 5 weeks without obvious success. The results were satisfactory: five patients had total or almost total regression; the rest have had partial regression while treatment is still in progress. A flu-like syndrome with fever, rhinitis, etc. accompanied the injections in some patients. The symptoms were controlled with paracetamol as necessary. Mild, transient leukopenia occurred in some children as well, but subsided after cessation of therapy for 1 week. IFN-A2a appears to be a promising and well-tolerated element in the treatment of life-threatening hemangiomas in infancy and childhood.
血管瘤是婴儿期最常见的肿瘤。大多数血管瘤增殖8至18个月，然后在接下来的5至8年中缓慢消退。到目前为止，类固醇一直是既定的治疗方法，但已有一些关于使用α-2a干扰素（IFN-A2a）治疗此类肿瘤的报道。为了评估IFN-A2a治疗婴幼儿巨大血管瘤的疗效，我们对10例年龄在4小时至6.5岁、患有危及生命的身体各部位血管瘤的患者使用了该药。使用的剂量为每两天皮下注射3 MU/m²体表面积。所有儿童此前均接受过2至5周的皮质类固醇治疗，但效果不明显。结果令人满意：5例患者完全或几乎完全消退；其余患者在治疗仍在进行时部分消退。部分患者注射后出现类似流感的综合征，伴有发热、鼻炎等。必要时用对乙酰氨基酚控制症状。一些儿童还出现了轻度、短暂的白细胞减少，但在停药1周后消退。IFN-A2a似乎是治疗婴幼儿危及生命的血管瘤的一种有前景且耐受性良好的药物。
